ArticleEuropean journal of case reports in internal medicine2025
Pseudohypoaldosteronism type II: The Relevance of A Challenging Diagnosis.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating multi-ancestry common and rare variant mapping accelerates therapeutic target discovery.medRxiv : the preprint server for health sciences · 2026Article
- Diagnostic Challenges in Severe Electrolyte Imbalance in Early Infancy: A Case Report of Secondary Pseudohypoaldosteronism.Pediatric reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudohypoaldosteronism type II (PHA II) is a rare genetic syndrome caused by mutations in the LEARNING POINTS: We report a case of a young woman with PHA II caused by a novel variant in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.